Idera is advancing to the clinic in autoimmune diseases and certain genetically defined forms of B-cell lymphoma: activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL), Waldenström’s macroglobulinemia and others. Its lead drug candidate, IMO-8400, is designed to modulate immune responses through Toll-like receptors (TLRs).
|September 26, 2016 at 9:00 a.m. ETIdera Pharmaceuticals, Inc. Corporate Conference Call|
|August 16, 2016 at 12:45 p.m. ETIdera at the 2016 Wedbush PacGrow Healthcare Conference|
|There are currently no events scheduled.|